Chips, Memory, Tech: Down, Down, Down; Upside, Downside Movers in A.M.

Upside

– $HIHO +34% (extends rally tied to a $7M strategic investment, planned legacy-business spin-off and $2M cash dividend)

– $LXEO +24% (interim Phase 1/2 data showed an 80% mean reduction in non-sustained ventricular tachycardia, with the FDA open to a surrogate endpoint supporting potential accelerated approval)

– $TU +18% (Québecor disclosed an unsolicited nonbinding acquisition proposal implying an approximately 60% premium; the board is reviewing the offer and other strategic alternatives)

– $HELP +13% (positive Phase 3 APPROACH data met the primary and key secondary endpoints)

– $DRTS +12% (interim recurrent-glioblastoma data showed a 100% response rate in the first six evaluable patients, with all treated patients alive and no unanticipated serious adverse events)

– $AIMD +8.1% (extends gains after securing its largest-ever order, a $9M agreement for 5,000 additional AI Nose systems)

– $TTWO +3.1% (rallies ahead of the November 19 Grand Theft Auto VI launch after management said presales were far above expectations)

– $JNJ +1.2% (reported talks to acquire Ollin Biosciences for up to $3.4B)

Downside

– $DVLT -34% (Nasdaq will suspend trading effective November 17 for bid-price noncompliance, with the shares expected to shift to the OTC market)

– $MBOT -29% (Q3 revenue fell sequentially to $72K, the operating loss widened and results included an $815K inventory write-down)

– $SMMT -14% (FDA issued a Complete Response Letter for the ivonescimab-plus-chemotherapy application after overall survival failed to reach statistical significance)

– $MSTR -8.5%, $CRCL -8.3%, $BMNR -7.7%, $COIN -7.5%, $MARA -6.7%, $RIOT -6.1% (crypto-linked stocks fall as Bitcoin slides toward $64,000 and extends its multiweek decline)

– $NBIS -8.3%, $CRWV -7.5%, $AAOI -7.0%, $APLD -6.1%, $DELL -4.8% (AI-infrastructure names extend their selloff amid Nvidia leadership uncertainty and renewed capex, financing and debt concerns)

– $FORM -6.9%, $AXTI -7.8%, $MXL -7.0%, $AEHR -7.7% (semiconductor test, materials and connectivity suppliers fall with the broad AI-chip risk-off move ahead of NVDA earnings)

– $SNDK -6.9%, $MRVL -6.2%, $MU -6.5%, $WDC -5.8%, $STX -5.7%, $AMD -5.7% (chip, memory and storage names fall as turmoil around Nvidia continues to pressure the broader AI trade)

– $ARM -5.5%, $TSM -5.2%, $AMAT -5.2%, $LRCX -5.2% (chip-design, foundry and equipment names fall with the industrywide semiconductor rout)

– $INTC -5.4% (shareholders filed a proposed class action alleging the company concealed the impact of weak PC demand and excess inventory)

– $NVDA -4.3% (HSBC downgraded to Hold and CLSA cut its conviction rating and target as CEO-departure uncertainty persists ahead of earnings)

– $LHX -3.8% (administration officials suggested the company may bear responsibility for Friday’s nationwide FAA ground stop)

Select Premarket Movers

Upside

– $BKYI +76% (no clear fresh catalyst identified; unusually large, high-volume premarket move)

– $SSTI +51% (agrees to be acquired for $8.00 cash plus a contingent-value right worth up to another $3.00 per share)

– $SANG +39% (agrees to a $204M cash-and-stock takeover at an indicated 47% premium)

– $SMMT +18% ($2B strategic equity investment at an $18.36-equivalent share price plus an expanded oncology collaboration)

– $MSGY +15% (rebounds after the financing-driven selloff; $1M placement proceeds will fund a further acquisition)

– $FFAI +13% (no clear fresh catalyst identified; unusually large, high-volume premarket move)

– $MX +8.7% (rises on read-through from its strategic partner’s U.S. government silicon-carbide development award)

– $NVTS +8.7% (awarded a U.S. government program to develop next-generation 10-kV silicon-carbide power semiconductors)

– $IOVA +8.3% (no clear fresh catalyst identified after a clinical and regulatory-news check; unusually large, liquid biotech move)

– $KMX +5.6% (Q2 beat across the board as sales and profit topped expectations)

Downside

– $QURE -52%, CLPT -24% (FDA said the AMT-130 data package was inadequate to support accelerated approval in Huntington’s disease; CLPT falls on delivery-platform read-through)

– $JLHL -31% ($898K private placement includes shares and pre-funded warrants priced at $0.30, implying substantial dilution)

– $FICO -21%, EFX -4.0% (credit-data names fall as FHFA pushes broader VantageScore use and moves to weaken FICO’s mortgage-scoring monopoly)

Position: None